Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384834 | 1.00 | ADRB2 (0.45) | ADRB2MEN1KMT2AACHEADRB1 | |
| SCHEMBL4386793 | 0.92 | ADRB2 (0.46) | ADRB2ACHEADRB1 | |
| SCHEMBL4386789 | 0.92 | ADRB2 (0.46) | ADRB2ACHEADRB1 | |
| SCHEMBL4385606 | 0.88 | ADRB2 (0.45) | ADRB2ACHEADRB1 | |
| SCHEMBL4385609 | 0.88 | ADRB2 (0.45) | ADRB2ACHEADRB1 | |
| SCHEMBL4387427 | 0.87 | ADRB2 (0.45) | ADRB2ACHEADRB1 | |
| SCHEMBL4392383 | 0.87 | ADRB2 (0.45) | ADRB2ACHEADRB1 | |
| SCHEMBL4382838 | 0.86 | ADRB2 (0.52) | ADRB2ADRB1 | |
| SCHEMBL4387770 | 0.86 | ADRB2 (0.52) | ADRB2ADRB1 | |
| SCHEMBL4382769 | 0.86 | ADRB2 (0.52) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | ADRB2 731/4885MEN1 1255/4885KMT2A 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.